Jane Banerji

481 total citations
11 papers, 204 citations indexed

About

Jane Banerji is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jane Banerji has authored 11 papers receiving a total of 204 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Cancer Research, 8 papers in Oncology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jane Banerji's work include Breast Cancer Treatment Studies (10 papers), Cancer Treatment and Pharmacology (5 papers) and Advanced Breast Cancer Therapies (3 papers). Jane Banerji is often cited by papers focused on Breast Cancer Treatment Studies (10 papers), Cancer Treatment and Pharmacology (5 papers) and Advanced Breast Cancer Therapies (3 papers). Jane Banerji collaborates with scholars based in United Kingdom and Canada. Jane Banerji's co-authors include Judith M. Bliss, Lucy Kilburn, James P. Morden, Chris Holcombe, Maggie C.U. Cheang, Abigail Evans, Raghavan Vidya, Cliona Kirwan, Andrew Dodson and Mitch Dowsett and has published in prestigious journals such as Cancer Research, The Lancet Oncology and European Journal of Cancer.

In The Last Decade

Jane Banerji

10 papers receiving 199 citations

Peers

Jane Banerji

ONCOL

PRM

PFM

GENET

Shu-Lian Wang China

Andrea Stefek Germany

Maria Ekholm Sweden

Paula Cabrera‐Galeana Mexico

Naiba Nabieva Germany

Elena Aguirre Spain

Mathias Warm Germany

Eun-Shin Lee South Korea

Kris G. Samsom Netherlands

Cindy Fong Canada

Shu-Lian Wang China

Jane Banerji

106 ×0.7

155 ×1.2

ONCOL

39 ×0.6

PRM

52 ×1.2

PFM

21 ×0.8

GENET

Citations per year, relative to Jane Banerji Jane Banerji (= 1×) peers Shu-Lian Wang

Countries citing papers authored by Jane Banerji

Since Specialization

Citations

This map shows the geographic impact of Jane Banerji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane Banerji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane Banerji more than expected).

Fields of papers citing papers by Jane Banerji

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane Banerji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane Banerji. The network helps show where Jane Banerji may publish in the future.

Co-authorship network of co-authors of Jane Banerji

This figure shows the co-authorship network connecting the top 25 collaborators of Jane Banerji. A scholar is included among the top collaborators of Jane Banerji based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane Banerji. Jane Banerji is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Bliss, Judith M., Holly Tovey, Abigail Evans, et al.. (2023). Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015). Breast Cancer Research. 25(1). 39–39. 6 indexed citations

Smith, Ian, J.F.R. Robertson, Lucy Kilburn, et al.. (2020). Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. The Lancet Oncology. 21(11). 1443–1454. 147 indexed citations

Dowsett, Mitch, Judith M. Bliss, James P. Morden, et al.. (2018). Abstract GS1-03: Peri-operative aromatase inhibitor treatment in determining or predicting longterm outcome in early breast cancer – The POETIC* Trial (CRUK/07/015). Cancer Research. 78(4_Supplement). GS1–3. 15 indexed citations

Kilburn, Lucy, Maria Aresu, Jane Banerji, et al.. (2017). Can routine data be used to support cancer clinical trials? A historical baseline on which to build: retrospective linkage of data from the TACT (CRUK 01/001) breast cancer trial and the National Cancer Data Repository. Trials. 18(1). 561–561. 7 indexed citations

Bliss, Judith M., Jane Banerji, Arielle S. Gillman, & James P. Morden. (2017). Accelerated versus standard epirubicin followed by CMF versus capecitabine as adjuvant therapy of breast cancer: results of the randomised UK TACT2 trial (CRUK/05/19).

Bliss, Judith M., James P. Morden, Abigail Evans, et al.. (2017). Abstract P2-05-01: Clinico-pathological relationships with Ki67 in POETIC (CRUK/07/015) – Critical lessons for assessing Ki67 for prognosis and as a pharmacodynamic marker. Cancer Research. 77(4_Supplement). P2–5. 3 indexed citations

Kilburn, Lucy, Jane Banerji, & Judith M. Bliss. (2014). The challenges of long-term follow-up data collection in non-commercial, academically-led breast cancer clinical trials: the UK perspective. Trials. 15(1). 379–379. 8 indexed citations

Canney, Peter, Robert E. Coleman, James P. Morden, et al.. (2012). 200 TACT2 Trial in Early Breast Cancer (EBC): Differential Rates of Amenorrhoea in Premenopausal Women Following Adjuvant Epirubicin (E) or Accelerated Epirubicin (aE) Followed by Capecitabine (X) or CMF (CRUK/05/019). European Journal of Cancer. 48. S102–S102. 6 indexed citations

Cameron, David, Peter Barrett‐Lee, Peter Canney, et al.. (2012). Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). Cancer Research. 72(24_Supplement). S3–3. 9 indexed citations

10.

Bliss, Judith M., Peter Canney, G. Velikova, et al.. (2010). Abstract P5-10-07: TACT2 Randomised Adjuvant Trial in Early Breast Cancer (EBC): Tolerability and Toxicity of Standard 3 Weekly Epirubicin (E) Versus Accelerated Epirubicin (aE) Followed by Capecitabine (X) or CMF in 129 UK Hospitals (CRUK/05/019). Cancer Research. 70(24_Supplement). P5–10. 1 indexed citations

11.

Cameron, David, Peter Barrett‐Lee, Galina Velikova, et al.. (2010). Abstract P5-10-06: TACT2 Randomised Adjuvant Trial in Early Breast Cancer (EBC): Tolerability and Toxicity of Standard 3 Weekly Epirubicin (E) Versus Accelerated Epirubicin (aE) in 129 UK Hospitals (4391 Patients) (CRUK/05/019). Cancer Research. 70(24_Supplement). P5–10. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact